Celldex Therapeutics reported $-23257000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Abbvie ABBV:US $ 4717M 357M
Agenus AGEN:US $ -35.46M 18.57M
Amgen AMGN:US $ 2500M 196M
Applied Genetic Technologies AGTC:US $ -13.58M 4.86M
Aptinyx Inc APTX:US $ -19379000 207K
Biocept BIOC:US $ -2.71M 0.07M
Bristol Myers Squibb BMY:US $ 2553M 90M
Celldex Therapeutics CLDX:US $ -23.26M 2.92M
Cytrx CYTR:US -1294610 7.73M
Glaxosmithkline GSK:US $ 2801M 1906M
Immunogen IMGN:US $ -22.85M 11.7M
Merrimack Pharmaceuticals MACK:US $ -132000 341K
Nektar Therapeutics NKTR:US $ -116.56M 3.65M
Newlink Genetics NLNK:US -7731000 1.16M
Northwest Biotherapeutics NWBO:US -11876000 1.18M
Pfizer PFE:US $ 9873M 5297M
Rigel Pharmaceuticals RIGL:US $ -26.26M 4.84M
Seattle Genetics SGEN:US $ -133.05M 39.02M